TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05442515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).
Study: NCT04724928

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Metastasis directed therapy (MDT)
Description: Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Concurrently, the oligometastasis will be treated with stereotactic body radiotherapy or metastasectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards regular follow up is performed.
Study: NCT06156410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles. If still on study therapy the participants will continue with cabozantinib monotherapy for up to 12 total cycles.
Study: NCT06677060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat and dapagliflozin
Description: baxdrostat tablet and dapagliflozin tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo and dapagliflozin
Description: placebo tablet and dapagliflozin tablet
Study: NCT04452500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT108297
Description: CORT108297- 180mg daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- 180mg daily for 7 days
Study: NCT05296122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.
Description: The main purpose with the study is to investigate safety and feasibility of the TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation together with SmartTwist™ MR Hand Drill with the SmartTip™ MR Drill Kit for MR-guided laser thermal ablation of brain lesions.
Study: NCT05561114

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GIE Medical ProTractX3 TTS DCB
Description: Paclitaxel Coated Balloon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard Endoscopic Dilation
Study: NCT06157086

Intervention type: OTHER
Intervention: ofatumumab
Description: There is no treatment allocation. Participants with MS that initiated treatment with ofatumumabas per neurologist practice and regardless of the study protocol
Study: NCT06681870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1893
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1893
Description: Intravenous infusion
Study: NCT04809363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDPATH™
Description: Crohn's disease risk prediction tool.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Three blood samples will be drawn.
Study: NCT06627816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Description: efficacy of 3 drugs in preventing post-spinal anesthesia shivering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Description: efficacy of 3 drugs in preventing post-spinal anesthesia shivering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Description: efficacy of 3 drugs in preventing post-spinal anesthesia shivering
Study: NCT05909046

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immediate inpatient postpartum OGTT
Description: The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard of care 4-12 week postpartum OGTT
Description: Standard of care is 4-12 week outpatient postpartum OGTT
Study: NCT06692920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS stimulation
Description: * Standard of care DBS surgery~* stimulation through the DBS lead during their DBS lead surgery, the study team will use 2 sets of stimulation settings on each participant:~  1. Stimulation through the DBS contact whose electrical activity is the MOST similar to the area of the brain that controls movement~ 2. Stimulation through the DBS contact whose electrical activity is the LEAST similar to the area of the brain that controls movement
Study: NCT06699602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: cemiplimab IV flat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: fianilmab IV flat
Study: NCT06701422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative stimulation of the cervical spinal cord
Description: The surgeon will place spinal cord electrodes on the epidural surface, with stimulation sites identified using preoperative MRI. Recruitment curves will be generated by systematically increasing the stimulation intensity across various parameter combinations, including frequency, pulse count, pulse shape, and electrode-specific properties such as size, separation, and arrangement.
Study: NCT06693284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirdametinib and vorinostat
Description: short course of the combination of mirdametinib and vorinostat prior to the most appropriate standard of care treatment for the patient's specific tumor (typically localized radiation followed by surgical resection).
Study: NCT06423781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 75 mg taken once daily
Study: NCT06704217

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Six Spot Step Test
Description: The Six-Spot Step Test (SSST), which evaluates balance and functional ambulation, will be performed in an area 5 meters long and 1 meter wide. Five wooden cylinders will be arranged in a zig-zag pattern within this space, with the last cylinder positioned at the centerline. The participant will be asked to strike the wooden cylinders with the medial or lateral side of the same foot and push them outward. The test will be repeated twice with the dominant foot and twice with the non-dominant foot. A trial will be conducted before the test to familiarize participants with the procedure. A two-minute rest period between the test and trials will be provided to minimize fatigue effects. The test's inter-rater reliability will be assessed by two physiotherapists with more than 5 years of clinical experience, who will administer the test twice at 5-minute intervals.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oxford Hip Score
Description: The Oxford Hip Score will be used for functional level assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Description: The Berg Balance Scale (BBS) will be used to assess dynamic balance, which is reliable and commonly used within the orthopedic setting.
Study: NCT06704152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC + BSB-1001 Dose Escalation Cohort
Description: Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic stem cell transplant (HCT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC+BSB-1001 Expansion Dose
Description: Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic cell transplant (HCT).
Study: NCT06728579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement (MORE)
Description: eight weekly two-hour MORE sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: filled out up to 24 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: filled out up to 24 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy (SG)
Description: eight weekly two-hour SG sessions
Study: NCT06742762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: Dose 1
Study: NCT04960475

Intervention type: OTHER
Intervention: The MOS 36-Item Short From Health Survey (SF-36)
Description: The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. The SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.

Intervention type: OTHER
Intervention: The MOS 36-Item Short From Health Survey (SF-36)
Description: The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. The SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.
Study: NCT06539299

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Preservation
Description: After extracting a tooth, the alveolar socket is cleaned. A bone replacement material (Bio-Oss Collagen) is then placed into the socket and sutured with a collagen membrane (Mucograft-Seal). Patients will receive Antibiotics (Augmentin 875mg/125mg OR Dalacin C 300mg) and pain medication (Seractil forte 400 mg). Patients will be advised to carefully rinse with Chlorhexamed forte for one week. Sutures will be removed after two weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Preservation
Description: After extracting a tooth, the alveolar socket is cleaned. A bone replacement material (Bio-Oss Collagen) is then placed into the socket and sutured with a collagen membrane (Mucograft-Seal). Patients will receive Antibiotics (Augmentin 875mg/125mg OR Dalacin C 300mg) and pain medication (Seractil forte 400 mg). Patients will be advised to carefully rinse with Chlorhexamed forte for one week. Sutures will be removed after two weeks.
Study: NCT04800107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Curcumin-phosphatidylcholine
Description: 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule
Study: NCT05717647

Intervention type: OTHER
Intervention: Observational study: neuromonitoring
Description: collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
Study: NCT04987177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workload of Manual Wheelchair Propulsion
Description: Participants will complete 20 one-minute manual wheelchair propulsion bouts. Each one minute propulsion bout will be followed by a 2 minute rest period. Each propulsion bout will be at a different workload. After every 10 propulsion bouts, participants will be provided with an extended rest period (5 to 30 minutes). For each participant, the maximum workload to be tested is based on their estimated maximum workload. Estimate maximum workload is based on the HR-Workload relationship documented during a prior sub maximal test to 80% of age adjusted maximum heart rate.
Study: NCT05970601

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soup
Description: Intake of a single soup with different sodium chloride and potassium chloride content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soup
Description: Intake of a single soup with different sodium chloride and potassium chloride content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soup
Description: Intake of a single soup with different sodium chloride and potassium chloride content
Study: NCT05817526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMAC/ collagen
Description: Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft harvesting from chin
Description: Autograft
Study: NCT05058482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: embolism
Description: Cerebral arteriovenous malformation embolism

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: embolism
Description: Cerebral arteriovenous malformation embolism
Study: NCT05426122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Barley rice protein concentrate shake
Description: At one out of three test days barley rice protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein concentrate shake
Description: At one out of three test days pea protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
Study: NCT06070519

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CPET and related variables evaluation
Description: At the baseline visit ,CPET-related variables, echocardiographic, ECG, therapy and blood chemistry data will be collected. The baseline CPET will be repeated within 2 weeks. Patients will perform 4 follow up visits at 6, 12, 18 and 24 months after the baseline visit. At every study step, it will be performed:~* Echocardiography (LVEF)~* Blood sample (Na+, MDRD, Hb)~* Maximal ramp protocol CPET (peakVO2, VE/VCO2 slope)
Study: NCT05176821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole plus amoxicillin
Description: amoxicillin 750mg QID + esomeprazole 20mg QID for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole
Description: amoxicillin 1000mg BID + furazolidone 100mg BID + bismuth potassium citrate 600mg BID + esomeprazole 20mg BID for 14 days
Study: NCT05426122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate shake
Description: At one out of three test days whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
Study: NCT05051813

Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat measurements on each of the 3 ANTERION devices and 3 reference devices.

Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat measurements on each of the 3 ANTERION devices and 3 reference devices.
Study: NCT06755645

Intervention type: OTHER
Intervention: Lifestyle intervention
Description: A technological smart platform (app) that integrates diets, physical activity programs, sleep habits and other lifestyle interventions
Study: NCT06766812

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural set
Description: The epidural space will be identified at either the L3-L4 or L4-L5 interspace using the loss of resistance technique with an 18 Gauge Epidural needle.A test dose of 3 mL of 2% lidocaine with epinephrine will be administered to each participant to rule out intravascular or intrathecal placement of the catheter. This ensures the proper placement of the catheter before the full dose of analgesia is administered.Following the test dose, an initial bolus of 8 mL of 0.25% bupivacaine combined with 2 μg/mL fentanyl will be administered to provide effective labor analgesia. Subsequently, maintenance Dose 0.125% 2 ml/0.5 hr
Study: NCT05414331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuing all beta-blocker
Description: All beta-blockers will be stopped 2 months after CABG
Study: NCT04716959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prepectoral Prosthetic Breast Reconstruction
Description: The prepectoral approach involves placing the tissue expander on top of the pectoralis muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subpectoral Prosthetic Breast Reconstruction
Description: The subpectoral approach involves placing the tissue expander under the pectoralis muscle with or without acellular dermal matrix (ADM).
Study: NCT05087264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: ICG retention test and clearance test: intravenous injection, 0.5mg/l. Liver blood flow measurement: intravenous drip, dissolve 25mg ICG in 100ml injection water, and drip at a constant speed for about 50min to make the ICG concentration reach equilibrium.
Study: NCT06142500

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of biological samples of saliva from testicular cancer patients and from their first-degree family members
Description: The project aims to collect biological samples of saliva from testicular cancer patients and from their first-degree family members; demographic-clinical variables will be also collected in order to draft a comprehensive panel of genes and gene modifications related to the testicular cancer, combining this survey with a very detailed descprition of this cohort of patient in terms of clinical features and quality of life

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Analysis of biological samples of saliva from testicular cancer patients and from their first-degree family members
Description: The project aims to collect biological samples of saliva from testicular cancer patients and from their first-degree family members; demographic-clinical variables will be also collected in order to draft a comprehensive panel of genes and gene modifications related to the testicular cancer, combining this survey with a very detailed descprition of this cohort of patient in terms of clinical features and quality of life
Study: NCT05350618

Intervention type: OTHER
Intervention: Ultrasound evaluation
Description: A single transperineal ultrasound assessment session

Intervention type: OTHER
Intervention: Ultrasound evaluation
Description: A single transperineal ultrasound assessment session
Study: NCT06766357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine ophthalmic gel
Description: Administer to eyes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclosporine ophthalmic gel vehicle
Description: Administer to eyes
Study: NCT06771817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: WET may be an optimal treatment for pregnant or postpartum adolescents and youth with PTSD in a low resource setting. WET addresses many of the barriers above. It is delivered in just 5 sessions, with no homework, and may promote a sense of self-efficacy in adolescents and youth due to the nature of writing assignments and brief therapist involvement. It is attractive in resource-poor settings because just 10-15 min of direct therapist time per follow-up session is needed.
Study: NCT06775184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a native video image system
Description: The visualization of the glottic structures through the SaCoVLM™ imaging system is graded as follows: Grade1: Visibility of the lateral portion of the right epiglottic fold and part of the laryngeal inlet. Grade 2: Visibility of both epiglottic folds and part of the laryngeal inlet. Grade 3: Visibility of the laryngeal inlet and part of the vocal cords. Grade 4: Visibility of the entire vocal cords.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a native video image system
Description: The visualization of the glottic structures through the SaCoVLM™ imaging system is graded as follows: Grade1: Visibility of the lateral portion of the right epiglottic fold and part of the laryngeal inlet. Grade 2: Visibility of both epiglottic folds and part of the laryngeal inlet. Grade 3: Visibility of the laryngeal inlet and part of the vocal cords. Grade 4: Visibility of the entire vocal cords.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic bronchoscope
Description: The position of the i-Gel is checked using a fiberoptic endoscope